NCT05984485View on ClinicalTrials.gov

The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

766

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Rectal Cancer
Interventions
PROCEDURE

neoadjuvant chemotherapy plus total mesorectal excision

Neoadjuvant chemotherapy regimen recommended FOLFOX6, XELON, FOLFOX, mFOLFOX for 4-6 courses, and TME surgical treatment after preoperative tumor restaging 1-2 weeks after neoadjuvant chemotherapy.

PROCEDURE

total mesorectal excision

Standard total mesorectal excision

Trial Locations (6)

110004

RECRUITING

Shengjing Hospital of China Medical University, Shenyang

400042

RECRUITING

Daping Hospital, Amy Medeical Univerisity, Chongqing

421001

RECRUITING

The First Affiliated Hospital of University of South China, Hengyang

510655

RECRUITING

Sun yat-sen University, the Sixth Affiliated Hospital, Guangzhou

637000

RECRUITING

The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong

710061

RECRUITING

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

All Listed Sponsors
lead

Sun Yat-sen University

OTHER